GLP-1 Collective

Policy Tracker · Patient Lens · July 12, 2026

Twelve patients, two drugmakers, one claim about Ozempic and Wegovy prices

A patent fight over Eli Lilly's GLP-1 drugs is moving through court alongside the pricing cases.

Nothing new was filed in the last day. These are the 8 most recent developments affecting GLP-1 access that this tracker has not covered yet, across 1 category. Each entry links to the full record.

## Courts and enforcement

**[Amarillas sues Novo Nordisk over Ozempic pricing and marketing](/lawsuits/cl-73552364)**.

**[Novo Nordisk sued over Ozempic and Wegovy marketing claims](/lawsuits/cl-73546271)**.

**[ANTE challenges Eli Lilly's GLP-1 patents in court](/lawsuits/cl-73545832)**.

**[Bennett sues Novo Nordisk over Ozempic pricing and marketing](/lawsuits/cl-73545071)**.

**[Lewis sues Eli Lilly over Mounjaro and Zepbound](/lawsuits/cl-73544929)**.

**[Davis sues Eli Lilly over Mounjaro pricing and marketing](/lawsuits/cl-73548180)**.

**[Smith v. Eli Lilly, GLP-1 lawsuit details pending](/lawsuits/cl-73540300)**.

**[Novo Nordisk faces lawsuit over GLP-1 pricing and marketing](/lawsuits/cl-73539799)**.

26 further items in this category were tracked today and are listed on the site.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.